Journal
EPIGENOMICS
Volume 8, Issue 11, Pages 1519-1525Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/epi-2016-0071
Keywords
5-azacytidine; 5-aza-2 '-deoxycytidine; chondrosarcoma; DNA methylation; epigenetics
Categories
Funding
- Gattegno fund
- Wechsler fund
- Sarcoma Foundation of America (SFA)
- National Cancer Institute (NCI)/NIH [CA 151452-01]
- Sarcoma SPORE/NIH
- Academic Enrichment Fund of MGH Orthopaedics
Ask authors/readers for more resources
Chondrosarcoma (CS) is the second most common primary malignant bone tumor. Unlike other bone tumors, CS is highly resistant to conventional chemotherapy and radiotherapy, thus resulting in poor patient outcomes. There is an urgent need to establish alternative therapies for CS. However, the etiology and pathogenesis of CS still remain elusive. Recently, DNA methylation-associated epigenetic changes have been found to play a pivotal role in the initiation and development of human cancers, including CS, by regulating target gene expression in different cellular pathways. Elucidating the mechanisms of DNA methylation alteration may provide biomarkers for diagnosis and prognosis, as well as novel treatment options for CS. We have conducted a critical review to summarize the evidence regarding aberrant DNA methylation patterns as diagnostic biomarkers, predictors of progression and potential treatment strategies in CS.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available